MUTAGENIZED IL13-BASED CHIMERIC MOLECULES

摘要

This invention provides mutagenized interleukin 13 molecules that show
improved specificity for the restricted (IL4 independent) IL13 receptor and
reduced cross reactivity with the IL4/IL4 shared receptor. The mutagenized
IL13 molecules include one or more mutations in a domain that interacts with
the 140 kDa hIL4R.beta. or the hIL13R.alpha.1 subunit. These mutagenized IL13
molecules provide effective targeting moieties in chimeric molecules (e.g.
fusion proteins) that specifically deliver effector molecules (e.g.
cytotoxins) to cells overexpressing IL13 receptors (e.g. cancer cells such as
gliomas).